AlphaLiquid®Detect is a tailored liquid biopsy platform for early monitoring of recurrence after cancer surgery.
Negotiable Min Order Quantity Unit
- Required Quantity
- Place of Origin
- South Korea
- Payment Terms
- Production method
- Shipping / Lead Time
- Negotiable / Negotiable
- Medical Test Kit
|Product name||AlphaLiquid® Detect||Certification||-|
|Category||Medical Test Kit||Material||-|
|Keyword||cancer diagnostics , minimal residual disease , early detection||Unit Size||-|
|Brand name||-||Unit Weigh||-|
|Supply type||Available||HS code||-|
A personalized liquid biopsy platform is available for early monitoring of cancer recurrence after surgery. This platform detects tumor specific genetic mutations in cancer tissues during surgery, creates personalized gene panels, and performs minimal residual disease (MRD) monitoring after surgery.The test results can guide adjustments in anticancer drug and treatment progress, ultimately improving the patient's survival rate.
The test detects specific mutations to monitor in the patient's surgical tissue and creates a personalized panel using our algorithm. This personalized panel includes a region where drug resistance mutations can be detected. The patient's blood is targetedly sequenced to determine if the patient has any minimal residual disease. With this bespoke panel, the patient can continuously monitor for recurrence.
AlphaLiquid® Detect is an industry-first personalized, hybrid-capture NGS based liquid biopsy test. This test is designed
for the detection and surveillance of minimal residual disease (MRD) in patients with stage I-III solid tumors. The assay
uses a personalized panel of up to 1,000 targets, which includes both patient-specific markers informed by tumor
analysis and additional therapeutic targets.
|Payment Options||T/T||Shipping time||Negotiable|
Covid 19 Detection
BIOCREDIT COVID-19 IgG+IgM Duo
I-STEM (Y-STEM) PRP KIT
PREGABLE Ovulation Pregnancy Tests Kit with APP, SmileReader
COVID 19 IgM / IgG RAPID KIT